9h (edited) • Peptide Tips
Split Dosing GLP-1s: Why Smaller, More Frequent Doses Work Better
Do your research subjects experience a crash around day 6 or 7?
It's a common pattern researchers observe...
Days 1-4: Strong response. Minimal appetite signaling. Low food-seeking behavior.
Days 5-6: Effects softening. Appetite signals returning.
Day 7: Significant hunger response. Waiting on next administration.
This isn't a flaw in the research protocol.
It's basic pharmacokinetics.
Here's what the data shows:
Even with tirzepatide's ~5-day half-life, by day 7, circulating levels drop to roughly 60-65% of peak concentration. Receptor occupancy decreases proportionally.
But what if you could maintain more stable levels throughout the research period?
Same total weekly dose. Same mg. Just redistributed.
→ Reduced peak-related side effects
→ No end-of-week trough effects
→ More consistent receptor activation
→ Flatter concentration curve
I wrote a deep dive breaking down:
✓ Why these compounds accumulate and why dose increases before week 4 skew results
✓ The math behind steady state
✓ Why clinical trials use once-weekly protocols (hint: it's about adherence, not optimization)
✓ Which research scenarios benefit from split dosing
✓ Practical protocols and considerations
Full article with all the mechanisms 👇
Drop a comment if you've experimented with split dosing in your research—curious what others have observed.
15
20 comments
Split Dosing GLP-1s: Why Smaller, More Frequent Doses Work Better
powered by
skool.com/peptide-price-9771
Premier peptide education hub. FREE courses on research peptides & GLP-1s. US supplier intel, safety protocols & expert community support. 🧬🚀
Suggested communities
Powered by